We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

65 hedge funds and large institutions have $242M invested in Intellia Therapeutics in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 14

40% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 10

5% more funds holding

Funds holding: 62 → 65 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

20% less capital invested

Capital invested by funds: $302M → $242M (-$59.1M)

Holders
65
Holders Change
+3
Holders Change %
+4.84%
% of All Funds
1.73%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
21
Reduced
14
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$2.6M
2
SM
Sabby Management
Florida
+$2.03M
3
BIT
BlackRock Institutional Trust
California
+$1.29M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$677K
5
PAM
Panagora Asset Management
Massachusetts
+$605K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$2.13M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.3M
3
EA
Emerald Acquisition
Washington
-$873K
4
GL
GLG LLC
New York
-$730K
5
LCM
Landscape Capital Management
New Jersey
-$582K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$89.6M +$201K +10,400 +0.2%
O
2
OrbiMed
New York
$45.3M – – –
BBA
3
Baker Bros. Advisors
New York
$18.1M – – –
Temasek Holdings
4
Temasek Holdings
Singapore
$13.5M – – –
FCMI
5
Foresite Capital Management III
California
$13M – – –
BA
6
BlackRock Advisors
Delaware
$10.5M +$13.7K +707 +0.1%
Vanguard Group
7
Vanguard Group
Pennsylvania
$7.48M +$446K +23,066 +6%
Franklin Resources
8
Franklin Resources
California
$5.11M – – –
Morgan Stanley
9
Morgan Stanley
New York
$4.81M -$359K -18,532 -6%
AG
10
Artal Group
Luxembourg
$3.49M -$387K -20,000 -9%
EC
11
EcoR1 Capital
California
$3.42M -$2.13M -109,837 -35%
BFA
12
BlackRock Fund Advisors
California
$3.01M +$253K +13,069 +8%
Goldman Sachs
13
Goldman Sachs
New York
$2.66M +$236K +12,189 +8%
SAM
14
Sectoral Asset Management
Quebec, Canada
$2.32M – – –
Millennium Management
15
Millennium Management
New York
$2.29M +$2.6M +134,240 New
BIT
16
BlackRock Institutional Trust
California
$2.12M +$1.29M +66,572 +115%
SM
17
Sabby Management
Florida
$1.78M +$2.03M +104,841 New
State Street
18
State Street
Massachusetts
$1.61M +$459K +23,706 +33%
Invesco
19
Invesco
Georgia
$1.41M -$387 -20 -0%
Neuberger Berman Group
20
Neuberger Berman Group
New York
$1.34M +$19.4K +1,000 +1%
Northern Trust
21
Northern Trust
Illinois
$1.28M -$5.55K -287 -0.4%
TCM
22
Tekla Capital Management
Massachusetts
$1.22M -$290K -15,000 -17%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$1.17M +$26.3K +1,357 +2%
Alyeska Investment Group
24
Alyeska Investment Group
Illinois
$596K +$677K +35,000 New
PAM
25
Panagora Asset Management
Massachusetts
$532K +$605K +31,250 New
1
2 3

NTLA Hedge Fund Activity: Q3 2016 in Review

65 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2016, worth a combined $242M — down 20% from $302M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new NTLA positions and 10 closed out — a net gain of 4 holders — while 21 added to existing stakes and 14 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $2.6M. The largest seller was EcoR1 Capital, cutting an estimated $2.13M.

  • 65 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2016, up from 62 in Q2 2016.
  • Funds reported $242M of Intellia Therapeutics stock for Q3 2016, down 20% quarter-over-quarter.
  • 14 funds opened new Intellia Therapeutics positions in Q3 2016 and 10 closed out, a net change of +4 holders.
  • The largest Intellia Therapeutics buyer in Q3 2016 was Millennium Management, an estimated $2.6M added.
  • The largest Intellia Therapeutics seller in Q3 2016 was EcoR1 Capital, an estimated $2.13M sold.

Based on aggregated 13F filings for Q3 2016.